指南与共识消化、代谢与肾脏急症重症综合管理与镇静镇痛

钠-葡萄糖协同转运蛋白-2(SGLT-2)抑制剂用于成人慢性肾脏病:临床实践指南

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline.
指南 / 共识 · BMJ · 2024-10-01
一句话结论指南基于KDIGO风险分层推荐:高危和极高危成人CKD推荐使用SGLT-2抑制剂(强推荐),中危和低危建议使用(弱推荐),无论是否合并2型糖尿病。

该指南由国际专家组遵循可信指南标准和GRADE方法制定,采用KDIGO分类系统将成人CKD按进展和并发症风险分为低、中、高、极高危四层,并结合五年绝对效应和患者价值观给出分层推荐。基于13项试验、29614例参与者的系统评价和配对Meta分析显示,极高危患者使用SGLT-2抑制剂可降低全因死亡、心血管死亡、心衰住院、肾衰竭、非致死性心肌梗死和非致死性卒中;高危患者有类似获益但心衰住院和肾衰竭效果甚微;中低危患者可能降低全因死亡和非致死性卒中。推荐适用于所有成人CKD, irrespective of type 2 diabetes status。临床需基于eGFR和白蛋白尿程度进行风险分层以指导共享决策。

要点

  • 极高危成人CKD:推荐使用SGLT-2抑制剂(强推荐),可降低全因死亡、心血管死亡、心衰住院、肾衰竭、非致死性心肌梗死和非致死性卒中。
  • 高危成人CKD:推荐使用SGLT-2抑制剂(强推荐),多数获益类似,但对心衰住院和肾衰竭效果甚微。
  • 中危和低危成人CKD:建议使用SGLT-2抑制剂(弱推荐),可能降低全因死亡和非致死性卒中,其他获益结局效果甚微。
  • 推荐适用于所有成人CKD,无论是否合并2型糖尿病;应用前需按eGFR和白蛋白尿程度进行KDIGO风险分层。
  • SGLT-2抑制剂对需透析的急性肾损伤、骨折、下肢截肢、酮症酸中毒、生殖器感染或症状性低血容量影响甚微,但个体层面仍残留危害可能性。

适用人群与场景

  • 成人慢性肾脏病(CKD)患者,无论是否合并2型糖尿病。
  • 按KDIGO分类系统分为低危、中危、高危、极高危四个风险层,基于肾小球滤过率(估算或实测)和白蛋白尿程度。

诊断标准与关键阈值

  • 使用KDIGO分类系统对成人CKD进行风险分层:低危、中危、高危、极高危(基于CKD进展和相关并发症风险)。
  • 风险分层依据:肾小球滤过率(估算或实测)和白蛋白尿程度。

处置流程与药物剂量

  • 低危成人CKD:建议使用SGLT-2抑制剂(弱推荐)。
  • 中危成人CKD:建议使用SGLT-2抑制剂(弱推荐)。
  • 高危成人CKD:推荐使用SGLT-2抑制剂(强推荐)。
  • 极高危成人CKD:推荐使用SGLT-2抑制剂(强推荐)。
  • 应用推荐时需适当识别成人CKD、考虑潜在病因、基于肾小球滤过率和白蛋白尿程度进行风险分层。
  • 除风险分层外,可根据肾脏疾病程度和其他合并症进一步评估个体风险,以指导个体化决策和共享决策;可用风险计算器帮助估计CKD进展和并发症风险。

研究设计与关键结果

  • 指南专家组考虑了SGLT-2抑制剂治疗成人CKD五年内的获益和危害证据及背景因素,给出分层推荐。
  • 链接的系统评价和配对Meta分析纳入13项试验、29614例参与者,评估SGLT-2抑制剂在伴或不伴2型糖尿病的成人CKD中的获益和危害。
  • 极高危患者:中至高质量证据显示,与安慰剂或不含SGLT-2抑制剂的标准治疗相比,SGLT-2抑制剂降低全因死亡、心血管死亡、心衰住院、肾衰竭、非致死性心肌梗死和非致死性卒中。
  • 高危患者:中至高质量证据显示,SGLT-2抑制剂在多数结局上产生类似获益,但对心衰住院和肾衰竭效果甚微或无效果。
  • 中危和低危患者:中至高质量证据显示,SGLT-2抑制剂可能降低全因死亡和非致死性卒中,对其他获益结局效果甚微或无效果。
  • 危害结局缺乏风险分层估计,专家组因此考虑跨风险层汇总的绝对效应。
  • SGLT-2抑制剂对需透析的急性肾损伤、骨折、下肢截肢、酮症酸中毒、生殖器感染或症状性低血容量影响甚微或无影响,但个体患者层面仍残留危害可能性。

证据类型、等级与局限

  • 证据类型:临床实践指南,基于链接的系统评价和配对Meta分析(13项试验,29614例参与者)。
  • 证据分级:采用GRADE方法。
  • 推荐强度:低危和中危为弱推荐(支持);高危和极高危为强推荐(支持)。
  • 局限:危害结局缺乏风险分层估计,专家组使用跨风险层汇总的绝对效应。

对床旁实践的改变

  • 临床医生应识别成人CKD,考虑潜在病因,并基于肾小球滤过率(估算或实测)和白蛋白尿程度进行风险分层,以应用分层推荐。
  • 对于高危和极高危成人CKD,指南强推荐使用SGLT-2抑制剂;对于中危和低危,弱推荐建议使用。
  • 推荐适用于所有成人CKD, irrespective of type 2 diabetes status。
  • 可用风险计算器帮助估计个体CKD进展和并发症风险,以支持共享决策。

指南或共识出处

  • 指南名称:Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline(BMJ)。
  • 发布机构:国际专家组(包括患者、临床医生和方法学家)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

CLINICAL QUESTION: What is the impact of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on survival and on cardiovascular and kidneyoutcomes for adults living with chronic kidney disease (CKD)?

CURRENT PRACTICE: Few therapies slow kidney disease progression and improve long term prognosis for adults living with CKD. SGLT-2 inhibitors have demonstrated cardiovascular and kidney benefits in adults with CKD with and without type 2 diabetes. Existing guidance for SGLT-2 inhibitors does not account for the totality of current best evidence for adults with CKD and does not provide fully stratified treatment effects and recommendations across all risk groups based on risk of CKD progression and complications.

RECOMMENDATIONS: The guideline panel considered evidence regarding benefits and harms of SGLT-2 inhibitor therapy for adults with CKD over a five year period, along with contextual factors, and provided the following recommendations:1. For adults at low risk of CKD progression and complications, we suggest administering SGLT-2 inhibitors (weak recommendation in favour)2. For adults at moderate risk of CKD progression and complications, we suggest administering SGLT-2 inhibitors (weak recommendation in favour)3. For adults at high risk of CKD progression and complications, we recommend administering SGLT-2 inhibitors (strong recommendation in favour)4. For adults at very high risk of CKD progression and complications, we recommend administering SGLT-2 inhibitors (strong recommendation in favour).Recommendations are applicable to all adults with CKD, irrespective of type 2 diabetes status.

HOW THIS GUIDELINE WAS CREATED: An international panel including patients, clinicians, and methodologists produced these recommendations following standards for trustworthy guidelines and using the GRADE approach. The panel identified typical risk strata of adults with CKD (from low to very high risk of CKD progression and related complications) using the classification system developed by Kidney Disease Improving Global Outcomes (KDIGO), and applied an individual patient perspective in moving from evidence to recommendations. Effects of SGLT-2 inhibitors were interpreted in absolute terms applicable to different risk strata with varying baseline risks for outcomes of benefit over a five year period. The panel explicitly considered the balance of benefits, harms, and burdens of starting an SGLT-2 inhibitor, incorporating the values and preferences of adults with different risk profiles. Interactive evidence summaries and decision aids accompany multilayered recommendations, developed in an online authoring and publication platform (www.magicapp.org) that allows reuse and adaptation.

THE EVIDENCE: A linked systematic review and pairwise meta-analysis (13 trials including 29 614 participants) of benefits and harms associated with SGLT-2 inhibitors in adults with CKD with or without type 2 diabetes informed guidance. Among individuals at very high risk of CKD progression and complications, moderate to high certainty evidence shows SGLT-2 inhibitors (relative to placebo or standard care without SGLT-2 inhibitors) decrease all-cause and cardiovascular mortality, hospitalisation for heart failure, kidney failure, non-fatal myocardial infarction, and non-fatal stroke. Among individuals at high risk, moderate to high certainty evidence shows SGLT-2 inhibitors result in similar benefits across outcomes except demonstrating little or no effect on hospitalisation for heart failure and kidney failure. Among individuals at moderate and low risk, moderate to high certainty evidence shows SGLT-2 inhibitors probably reduce all-cause mortality and non-fatal stroke, with little or no effect for other outcomes of benefit. Risk-stratified estimates were unavailable for outcomes of harm; the panel therefore considered absolute effects summarised across risk strata. SGLT-2 inhibitors are associated with little or no effect on acute kidney injury requiring dialysis, bone fractures, lower limb amputations, ketoacidosis, genital infections, or symptomatic hypovolaemia, although a residual possibility of harms at the individual patient level remains.

UNDERSTANDING THE RECOMMENDATION: In order to apply recommendations, clinicians must appropriately identify adults with CKD, consider the underlying aetiology, and risk stratify them based on glomerular filtration rate (estimated or measured) and degree of albuminuria. In addition to classifying individuals into risk strata, further estimation of a given patient's risk based on the extent of their kidney disease and other comorbidities may be warranted to inform individual-level decisions and shared decision making. Available risk calculators may help estimate a given patient's risk of CKD progression and complications.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Agarwal A, Zeng X, Li S, et al. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline. BMJ. 2024. PMID: 39353639. doi:10.1136/bmj-2024-080257

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。